Abstract: The present invention relates to a pharmaceutical composition for the treatment of anaphylaxis formulated for rapid delivery, in one embodiment, the delivery vehicle is a rapidly dissolving film. The films contain an epinephrine or a novel epinephrine pro-drag for fee rapid treatment of anaphylaxis in a patient. This invention relates to pharmaceutical compositions made by modifying the physicochemical properties of epinephrine in order to enhance its permeability through biological membranes (sublingual and buccal membranes). Several prodrugs of epinephrine are shown by modifying the two hydroxyl (phenolic) groups in positions 3 and 4 on the benzene ring, by chemically reacting the two groups with several acid moieties to form an ester bond with different alkyl chains. The addition of an alkyl group will enhance the lipophilicity of epinephrine (increase log P) and will consequently increase its permeability through the biological membranes (sublingual and buccal tissues in the oral cavity).

Abstract: This invention relates to a pharmaceutical composition made of a clindamycin salt complexed with strongly acidic non-spherical resin particles, wherein predominantly all of the resin particles are less than 75 microns in diameter, to form clindamycin-resin complex, wherein in the clindamycin-resin complex provides for immediate release of the clindamycin in a target environment and at least one non-ionic excipient. In one embodiment, the inventive subject matter is an oral liquid pharmaceutical formulation made of a complex of clindamycin hydrochloride, a fractionated resin and excipients to stabilize the complex. The pharmaceutical formulation remains stable in deionized water until the dosage form reaches an ion-rich environment (stomach or intestine), there which the active ingredient clindamycin hydrochloride is released.